96.22
4.34 (4.72%)
| Previous Close | 91.88 |
| Open | 92.33 |
| Volume | 2,055,038 |
| Avg. Volume (3M) | 1,421,455 |
| Market Cap | 12,995,208,192 |
| Price / Earnings (TTM) | 31.14 |
| Price / Earnings (Forward) | 21.05 |
| Price / Sales | 4.67 |
| Price / Book | 2.85 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 7.39% |
| Operating Margin (TTM) | 16.43% |
| Diluted EPS (TTM) | 1.34 |
| Quarterly Revenue Growth (YOY) | -1.40% |
| Quarterly Earnings Growth (YOY) | 76.30% |
| Total Debt/Equity (MRQ) | 2.27% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 645.55 M |
| Levered Free Cash Flow (TTM) | 636.51 M |
| Return on Assets (TTM) | 5.84% |
| Return on Equity (TTM) | 4.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Globus Medical, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.20 |
|
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 0.69% |
| % Held by Institutions | 100.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 123.00 (Barclays, 27.83%) | Buy |
| Median | 112.00 (16.40%) | |
| Low | 87.00 (Freedom Capital Markets, -9.58%) | Hold |
| Average | 107.86 (12.10%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 92.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 26 Feb 2026 | 104.00 (8.09%) | Buy | 96.71 |
| Barclays | 25 Feb 2026 | 123.00 (27.83%) | Buy | 96.22 |
| Needham | 25 Feb 2026 | 114.00 (18.48%) | Buy | 96.22 |
| 30 Jan 2026 | 112.00 (16.40%) | Buy | 90.68 | |
| Canaccord Genuity | 09 Jan 2026 | 112.00 (16.40%) | Buy | 94.47 |
| 17 Dec 2025 | 105.00 (9.12%) | Buy | 85.06 | |
| Piper Sandler | 08 Jan 2026 | 115.00 (19.52%) | Buy | 94.62 |
| Freedom Capital Markets | 17 Dec 2025 | 87.00 (-9.58%) | Hold | 85.06 |
| RBC Capital | 17 Dec 2025 | 100.00 (3.93%) | Buy | 85.06 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HULLER KELLY | - | 96.22 | -20,000 | -1,924,400 |
| Aggregate Net Quantity | -20,000 | |||
| Aggregate Net Value ($) | -1,924,400 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 96.22 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HULLER KELLY | Officer | 25 Feb 2026 | Automatic sell (-) | 20,000 | 96.22 | 1,924,400 |
| HULLER KELLY | Officer | 25 Feb 2026 | Option execute | 20,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 07 Jan 2026 | Announcement | Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |